S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)

Nyxoah (NYXH) Competitors

$10.75
+0.35 (+3.37%)
(As of 03:59 PM ET)

NYXH vs. STVN, ATNFW, SXTPW, ACONW, AIMDW, DRTSW, ALVOW, ALVO, AONCW, and AONC

Should you be buying Nyxoah stock or one of its competitors? The main competitors of Nyxoah include Stevanato Group (STVN), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), Ainos (AIMDW), Alpha Tau Medical (DRTSW), Alvotech (ALVOW), Alvotech (ALVO), American Oncology Network (AONCW), and American Oncology Network (AONC). These companies are all part of the "medical" sector.

Nyxoah vs.

Stevanato Group (NYSE:STVN) and Nyxoah (NASDAQ:NYXH) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Stevanato Group and Nyxoah both received 25 outperform votes by MarketBeat users. However, 64.10% of users gave Stevanato Group an outperform vote while only 62.50% of users gave Nyxoah an outperform vote.

CompanyUnderperformOutperform
Stevanato GroupOutperform Votes
25
64.10%
Underperform Votes
14
35.90%
NyxoahOutperform Votes
25
62.50%
Underperform Votes
15
37.50%

Stevanato Group has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stevanato Group$1.17BN/A$157.62M$0.5945.31
Nyxoah$4.70MN/A-$46.77M-$1.68-6.40

Stevanato Group has a net margin of 13.43% compared to Stevanato Group's net margin of -993.28%. Nyxoah's return on equity of 14.31% beat Stevanato Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Stevanato Group13.43% 14.31% 8.18%
Nyxoah -993.28%-38.58%-31.24%

Nyxoah has a consensus price target of $20.60, indicating a potential upside of 106.21%. Given Stevanato Group's stronger consensus rating and higher probable upside, analysts clearly believe Nyxoah is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stevanato Group
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
Nyxoah
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Stevanato Group has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

In the previous week, Stevanato Group had 1 more articles in the media than Nyxoah. MarketBeat recorded 1 mentions for Stevanato Group and 0 mentions for Nyxoah. Nyxoah's average media sentiment score of 1.87 beat Stevanato Group's score of 0.00 indicating that Stevanato Group is being referred to more favorably in the media.

Company Overall Sentiment
Stevanato Group Very Positive
Nyxoah Neutral

Summary

Stevanato Group beats Nyxoah on 10 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NYXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NYXH vs. The Competition

MetricNyxoahSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market CapN/A$3.69B$4.79B$7.31B
Dividend YieldN/A2.21%2.92%4.01%
P/E Ratio-6.4013.74215.5516.08
Price / SalesN/A57.402,478.4089.30
Price / CashN/A43.3947.0134.82
Price / Book2.124.174.554.16
Net Income-$46.77M$3.75M$103.87M$214.16M
7 Day Performance19.31%-3.21%-4.32%-3.49%
1 Month Performance-35.74%-7.63%-5.89%-3.94%
1 Year Performance11.98%12.40%6.71%3.40%

Nyxoah Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STVN
Stevanato Group
0 of 5 stars
€29.00
-1.5%
N/A+6.0%$0.00$1.17B49.155,635
ATNFW
180 Life Sciences
0 of 5 stars
$0.01
flat
N/A-47.9%$0.00N/A0.004Gap Up
SXTPW
60 Degrees Pharmaceuticals
0 of 5 stars
$0.11
flat
N/AN/A$0.00$253,573.000.002Positive News
ACONW
Aclarion
0 of 5 stars
$0.03
flat
N/A-43.1%$0.00$75,404.000.004Positive News
Gap Up
AIMDW
Ainos
0 of 5 stars
$0.08
flat
N/A-75.2%$0.00$122,112.000.0046Positive News
DRTSW
Alpha Tau Medical
0 of 5 stars
$0.21
flat
N/A+6.8%$0.00N/A0.00121News Coverage
Gap Up
ALVOW
Alvotech
0 of 5 stars
$3.26
-14.7%
N/A+129.7%$0.00$91.43M0.00999News Coverage
Gap Down
ALVO
Alvotech
0.0994 of 5 stars
$12.73
+1.8%
$12.67
-0.5%
+28.8%$0.00$93.38M-5.241,026News Coverage
AONCW
American Oncology Network
0 of 5 stars
$0.31
-18.4%
N/AN/A$0.00$1.28B0.001,525Gap Up
AONC
American Oncology Network
0 of 5 stars
$5.39
+5.3%
N/AN/A$0.00$1.28B0.001,525Gap Down

Related Companies and Tools

This page (NASDAQ:NYXH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners